Valuation: Carmat SA

Market Cap 6.15M 6.89M 5.7M 5.19M 9.78M 655M 9.96M 68.59M 26.85M 341M 25.85M 25.33M 1.09B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 66.45M 54.92M 50.05M 94.27M 6.32B 95.97M 661M 259M 3.29B 249M 244M 10.5B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.1
Extreme 0.099
0.1
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
29.5
10 years 0.08
Extreme 0.085
40.06
Manager TitleAgeSince
Chief Executive Officer 55 01/09/2016
Director of Finance/CFO - 12/12/2018
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 02/01/2017
Director/Board Member 79 20/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
13/3/25 Sell

Chairman

1,343,333 2.3347%
13/3/25 Buy

Chairman

1,343,333 2.3347%
29/5/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-97.25% 7.08M
+2.29%+6.03%-21.45%+15.20% 178B
+1.29%+11.62%-1.13%+32.64% 121B
+4.12%+6.47%-20.75%+13.71% 108B
+0.41%+1.40%-45.37%-9.38% 75.7B
+1.56%+7.62%+7.39%+80.66% 64.15B
-1.75%-0.72%+17.66%+59.66% 53.49B
+2.58%+7.55%+2.87%-25.10% 51.45B
+3.43%+8.00%-14.09%+28.39% 41.68B
+5.08%+4.05%+32.47%+15.12% 31.5B
Average +1.90%+3.14%-4.24%+11.36% 72.47B
Weighted average by Cap. +2.04%+4.21%-10.53%+22.28%

Financials

2023 2024
Net sales 3.84M 4.3M 3.56M 3.24M 6.11M 409M 6.22M 42.82M 16.76M 213M 16.14M 15.81M 680M 7.34M 8.24M 6.81M 6.2M 11.69M 783M 11.9M 81.96M 32.08M 408M 30.89M 30.26M 1.3B
Net income -53.87M -60.42M -49.94M -45.51M -85.72M -5.74B -87.26M -601M -235M -2.99B -227M -222M -9.54B -51.4M -57.64M -47.64M -43.42M -81.78M -5.48B -83.25M -574M -225M -2.85B -216M -212M -9.11B
Net Debt 49.64M 55.67M 46.01M 41.93M 78.98M 5.29B 80.41M 554M 217M 2.76B 209M 205M 8.79B 53.1M 59.55M 49.22M 44.86M 84.49M 5.66B 86.02M 593M 232M 2.95B 223M 219M 9.41B
Projected Income Statement - Annual - Carmat SA
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock